First Trust Nasdaq Pharmaceuticals ETF
FTXH
16 hedge funds and large institutions have $8.23M invested in First Trust Nasdaq Pharmaceuticals ETF in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
11% less funds holding
Funds holding: 18 → 16 (-2)
24.93% less ownership
Funds ownership: 70.67% → 45.74% (-25%)
49% less capital invested
Capital invested by funds: $16M → $8.23M (-$7.79M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$607K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$423K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$61.8K |
| 4 |
IAN
Integrated Advisors Network
Dallas,
Texas
|
+$21K |
| 5 |
ADL
Asset Dedication LLC
San Francisco,
California
|
+$5.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$4.37M |
| 2 |
LJAC
L.J. Altfest & Co
New York
|
-$4.04M |
| 3 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$243K |
| 4 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
-$207K |
| 5 |
LPL Financial
San Diego,
California
|
-$41.2K |
FTXH Hedge Fund Activity: Q3 2021 in Review
16 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2021, worth a combined $8.23M — down 49% from $16M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FTXH and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $607K. The largest seller was International Assets Investment Management, exiting entirely with an estimated $4.37M sold.
- 16 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2021, down from 18 in Q2 2021.
- Funds reported $8.23M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2021, down 49% quarter-over-quarter.
- 1 fund opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2021 and 3 closed out, a net change of -2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2021 was Citadel Advisors, an estimated $607K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2021 was International Assets Investment Management, an estimated $4.37M sold.
Based on aggregated 13F filings for Q3 2021.